205 - New Therapies for Bad Bugs

Moderator(s)

• 

  Wesley Kufel, Pharm.D., BCPS, BCIDP

  Clinical Associate Professor
  Binghamton University School of Pharmacy Sciences
  Binghamton, NY, United States
• 

  Paul Bollyky, MD/PhD

  Professor
  Stanford University
  Stanford, CA, United States

Presentations:

• 10:30 AM – 10:42 AM US PT

  Pseudomonas aeruginosa-specific CRISPR-Cas3 bacteriophage cocktail developed to treat respiratory and bloodstream infections
  

  Co-Author: Lana McMillan, PhD – Locus Biosciences

  Co-Author: Taylor Penke, PhD – Locus Biosciences

  Co-Author: Hannah Tuson, PhD – Locus Biosciences

  Co-Author: Robert McKee, PhD – Locus Biosciences

  Co-Author: Ethan Baker, M.S. – Locus Biosciences

  Presenting Author: Ashley Trama, PhD, MBA – Locus Biosciences
• 10:42 AM – 10:54 AM US PT

  Bacteriophages as Drug Delivery Vehicles for Polymyxin B
  

  Presenting Author: Yanxi Yang, PhD Candidate (he/him/his) – UCLA

  Co-Author: Irene Chen, MD. Ph.D. – UCLA
• 10:54 AM – 11:06 AM US PT

  Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024)
  

  Co-Author: Ecem Buyukyanbolu, MD – Hartford Hospital

  Co-Author: Jill Argotsinger, PharmD, BCIDP – Advocate Lutheran General Hospital

  Co-Author: Eric T. Beck, PhD – Department of Microbiology, ACL Laboratories

  Co-Author: Robin R. Chamberland, PhD D(ABMM) – Saint Louis University School of Medicine

  Co-Author: Andrew E. Clark, PhD, D(ABMM) – University of Texas Southwestern Medical Center

  Co-Author: Philip Gialanella, BS MS – Montefiore Medical Center, Albert Einstein College of Medicine

  Co-Author: Matthew Loeb, n/a – Kansas University Medical Center

  Co-Author: Amy Sears, n/a – Kansas University Medical Center

  Co-Author: Amanda Harrington, PhD – Loyola University Chicago

  Co-Author: Romney Humphries, PhD, D(ABMM), M(ASCP) – Vanderbilt University Medical Center

  Co-Author: Wesley D. Kufel, Pharm.D., BCPS, BCIDP – Binghamton University School of Pharmacy Sciences

  Co-Author: Scott W. Riddell, Ph.D. – State University of New York Upstate Medical University

  Co-Author: A. Brian Mochon, PhD – University of Arizona College of Medicine

  Co-Author: Christine A. Vu, PharmD – Jackson Memorial Hospital

  Co-Author: Lilian M. Abbo, MD, MBA (she/her/hers) – University of Miami Miller School of Medicine, Jackson Health System

  Co-Author: Octavio Martinez, Ph.D., ABMM – Jackson Health System/University of Miami

  Co-Author: Jamie Marino, PhD – Weill Cornell Medicine

  Co-Author: Lars Westblade, PhD – Weill Cornell Medicine

  Co-Author: David P. Nicolau, PharmD – Hartford Hospital

  Presenting Author: Tomefa E. Asempa, PharmD – Hartford Hospital
• 11:06 AM – 11:18 AM US PT

  Efficacy of Gepotidacin versus Nitrofurantoin in a Nitrofurantoin Not Susceptible Population: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection
  

  Presenting Author: Jeremy Dennison, MD PhD – GSK, Brentford, UK

  Co-Author: Amanda Sheets, PhD – GSK, Collegeville, PA, USA

  Co-Author: Sarah Watts, MSc – GSK

  Co-Author: Nicole E. Scangarella-Oman, MS (she/her/hers) – GlaxoSmithKline plc.

  Co-Author: Deborah Butler, PharmD – GSK

  Co-Author: John Breton, MCM – GSK

  Co-Author: Salim Janmohamed, MD – GSK, Brentford, UK
• 11:18 AM – 11:30 AM US PT

  Cefiderocol Retains in vitro Activity Against Enterobacterales Non-Susceptible to β-lactam-β-lactamase Inhibitor Combinations
  

  Presenting Author: Boudewijn L. DeJonge, PhD (he/him/his) – Shionogi Inc.

  Co-Author: Sean T. Nguyen, PharmD – Shionogi Inc.

  Co-Author: Jason J. Bryowsky, PharmD, MS – Shionogi Inc.

  Co-Author: Joshua Maher, PhD – JMI Laboratories

  Co-Author: Rodrigo E. Mendes, PhD (he/him/his) – Element, Iowa City (JMI Laboratories)

  Co-Author: Christopher M. Longshaw, PhD – Shionogi B.V.

  Co-Author: Miki Takemura, n/a – Shionogi & Co., Ltd

  Co-Author: Yoshinori Yamano, PhD (he/him/his) – Shionogi & Co., Ltd.
• 11:30 AM – 11:43 AM US PT

  The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Acinetobacter baumannii Enriched in Isolates with Reduced Cefiderocol Susceptibility
  

  Co-Author: Takafumi Hara, MSc (he/him/his) – Shionogi & Co., Ltd.

  Co-Author: Naoki Ishibashi, MD – Pharmaceutical Research Division

  Co-Author: Dai Miyagawa, n/a – Shionogi & Co., Ltd.

  Co-Author: Motoyasu Onishi, PhD – Shionogi & Co., Ltd.

  Co-Author: Olga Lomovskaya, PhD – Qpex Biopharma Inc.

  Presenting Author: Yoshinori Yamano, PhD (he/him/his) – Shionogi & Co., Ltd.